These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 32979653)

  • 1. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials.
    Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP
    Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional outcome measures in young, steroid-naïve boys with Duchenne muscular dystrophy.
    Mayhew AG; Moat D; McDermott MP; Eagle M; Griggs RC; King WM; James MK; Muni-Lofra R; Shillington A; Gregson S; Pallant L; Skura C; Staudt LA; Eichinger K; McMurchie H; Rabb R; Di Marco M; Brown S; Zanin R; Arnoldi MT; McIntyre M; Wilson A; Alfano LN; Lowes LP; Blomgren C; Milev E; Iodice M; Pasternak A; Chiu A; Lehnert I; Claus N; Dieruf KA; Rolle E; Nicorici A; Andres B; Hobbiebrunken E; Roetmann G; Kern V; Civitello M; Vogt S; Hayes MJ; Scholtes C; Lacroix C; Gunn T; Warner S; Newman J; Barp A; Kundrat K; Kovelman S; Powers PJ; Guglieri M;
    Neuromuscul Disord; 2022 Jun; 32(6):460-467. PubMed ID: 35618576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    Muntoni F; Domingos J; Manzur AY; Mayhew A; Guglieri M; ; Sajeev G; Signorovitch J; Ward SJ
    PLoS One; 2019; 14(9):e0221097. PubMed ID: 31479456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study.
    Mazzone E; Vasco G; Sormani MP; Torrente Y; Berardinelli A; Messina S; D'Amico A; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Bonfiglio S; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Gasperini S; Previtali S; Napolitano S; Martinelli D; Bruno C; Vita G; Comi G; Bertini E; Mercuri E
    Neurology; 2011 Jul; 77(3):250-6. PubMed ID: 21734183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
    Arora H; Willcocks RJ; Lott DJ; Harrington AT; Senesac CR; Zilke KL; Daniels MJ; Xu D; Tennekoon GI; Finanger EL; Russman BS; Finkel RS; Triplett WT; Byrne BJ; Walter GA; Sweeney HL; Vandenborne K
    Muscle Nerve; 2018 Nov; 58(5):631-638. PubMed ID: 29742798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration.
    Goemans N; Wong B; Van den Hauwe M; Signorovitch J; Sajeev G; Cox D; Landry J; Jenkins M; Dieye I; Yao Z; Hossain I; Ward SJ;
    PLoS One; 2020; 15(6):e0232870. PubMed ID: 32555695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Longitudinal Study of Quantitative Muscle Strength and Functional Motor Ability in Ambulatory Boys with Duchenne Muscular Dystrophy.
    Buckon CE; Sienko SE; Fowler EG; Bagley AM; Staudt LA; Sison-Williamson M; Heberer KR; McDonald CM; Sussman MD
    J Neuromuscul Dis; 2022; 9(2):321-334. PubMed ID: 34924398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.
    Rabbia M; Guridi Ormazabal M; Staunton H; Veenstra K; Eggenspieler D; Annoussamy M; Servais L; Strijbos P
    J Neuromuscul Dis; 2024; 11(3):701-714. PubMed ID: 38640165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
    Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of motor proficiency and functional ambulation in Duchenne muscular dystrophy with healthy peers.
    Yildiz S; Sahin S; Bulut N; Tunca Yilmaz O; Karaduman AA; Akel BS
    Somatosens Mot Res; 2020 Dec; 37(4):252-256. PubMed ID: 32583706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids.
    Duong T; Canbek J; Fernandez-Fernandez A; Henricson E; Birkmeier M; Siener C; Tesi Rocha C; McDonald C; Gordish-Dressman H;
    J Neuromuscul Dis; 2022; 9(1):147-159. PubMed ID: 34719507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.
    Connolly AM; Florence JM; Cradock MM; Malkus EC; Schierbecker JR; Siener CA; Wulf CO; Anand P; Golumbek PT; Zaidman CM; Philip Miller J; Lowes LP; Alfano LN; Viollet-Callendret L; Flanigan KM; Mendell JR; McDonald CM; Goude E; Johnson L; Nicorici A; Karachunski PI; Day JW; Dalton JC; Farber JM; Buser KK; Darras BT; Kang PB; Riley SO; Shriber E; Parad R; Bushby K; Eagle M;
    Neuromuscul Disord; 2013 Jul; 23(7):529-39. PubMed ID: 23726376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.
    Bendixen RM; Lott DJ; Senesac C; Mathur S; Vandenborne K
    Disabil Rehabil; 2014; 36(22):1918-23. PubMed ID: 24499260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.
    Mazzone E; Martinelli D; Berardinelli A; Messina S; D'Amico A; Vasco G; Main M; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Carlesi A; Bonetti AM; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Pasquini E; Bruno C; Vita G; de Waure C; Bertini E; Mercuri E
    Neuromuscul Disord; 2010 Nov; 20(11):712-6. PubMed ID: 20634072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.